You searched for "retinopathy"

756 results found

A life outside ophthalmology

Lloyd Paul Aiello. It was an absolute privilege to speak to Lloyd Paul Aiello, Professor of Ophthalmology, Harvard Medical School, and Vice President of Ophthalmology and Director, Beetham Eye Institute, Joslin Diabetes Center, USA. Prof Aiello is a third-generation ophthalmologist,...

Ophthalmology elective: A reflection from Kilimanjaro, Tanzania

I was fortunate enough to undertake an eight-week ophthalmology elective at the Kilimanjaro Christian Medical Centre (KCMC) in Moshi, Tanzania. It was an unforgettable two months, filled with once-in-a-life-time experiences and also the opportunity to gain invaluable clinical knowledge. KCMC...

Study calls for thorough investigation of patients with early signs of retinal vascular disease

Patients with the eye condition Paracentral Acute Middle Maculopathy (PAMM) would benefit from further investigation, as their risk of heart attacks and strokes may be greater than previously shown, suggests a new study led by researchers at Moorfields Eye Hospital NHS Foundation Trust.

Fingolimod: ocular adverse effects

In this article the authors review the ocular side-effects of Fingolimod which is an oral immunomodulating drug used in the management of relapsing-remitting multiple sclerosis (RRMS). Fingolimod-associated macular oedema (FAME) is the most common ocular side-effect linked to this drug....

Learning from litigation: ocular drug toxicity

Being the subject of litigation is stressful and upsetting. Having to look back over your previous decisions and justify the care you delivered in good faith can be difficult. Sadly, we all live with the sword of Damocles above us...

Tocilizumab in Graves’ orbitopathy

This prospective European study looks at the response to tocilizumab in corticosteroid-resistant disease. Tocilizumab (TCZ) is a monoclonal antibody that competitively inhibits IL-6 binding to its receptor. Unlike teprotumumab, the advantage of TCZ is that it is already used within...

Semaglutide and vision loss: A new concern for NAION risk?

This article has been verified for CPD. Click the button below to answer a few short questions and download a form to be included in your CPD folder. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as transformative agents in...

Shedding light on Wolfram syndrome: The unveiling of a delayed diagnosis

Wolfram syndrome 1 (WS1) was first described by Wolfram and Wagener in 1938 and it’s a rare neurodegenerative, progressive disorder, also known as DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, and deafness) [1]. We present an atypical case of WS...

My top five: Uses of artificial intelligence in ophthalmology

Artificial Intelligence (AI) has emerged as a prominent topic of discussion within the field of ophthalmology, captivating researchers and practitioners alike. Although recent attention has been drawn to the integration of AI in ophthalmology, it’s important to recognise that AI...

From the seas to OCTs, a journey from working in TV to creating teaching in ophthalmology

To relaunch our Allied Professionals section, Paul Dimmock from Gloucestershire discusses his unique role with the Gloucestershire Retinal Education Group. In Gloucestershire we have a collection of ophthalmic-targeted departments led by Professor Peter Scanlon, Clinical Director of the NHS Diabetic...

My Top Five: Uses of artificial intelligence in ophthalmology

Artificial Intelligence (AI) has emerged as a prominent topic of discussion within the field of ophthalmology, captivating researchers and practitioners alike. Although recent attention has been drawn to the integration of AI in ophthalmology, it’s important to recognise that AI...

The International Centre for Eye Health: weaving the global threads together

The VISION 2020 LINKS & Networks Programme has been writing regular articles in Eye News about its capacity-strengthening activities in low- and middle-income countries (LMICs) for more than a decade. This, the first International Issue, is a landmark for Eye...